Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?

This publication has 29 references indexed in Scilit:

• Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical Specialties
  Clinical Cancer Research, 2007
• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007
• Phase 2 trial of Allovectin-7 in advanced metastatic melanoma
  Melanoma Research, 2006
• What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials
  Journal of Clinical Oncology, 2006
• Genomic Profiling of Cancer: What Next?
  Journal of Clinical Oncology, 2005
• Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
  Clinical Cancer Research, 2004
• Oncology's trials
  Nature Reviews Drug Discovery, 2003
• Molecular Oncodiagnostics: Where We Are and Where We Need to Go
  Journal of Clinical Oncology, 2003
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
  Clinical Pharmacology & Therapeutics, 2001
• Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer Agents
  JNCI Journal of the National Cancer Institute, 1993